aTyr Pharma
ATYR
24 hedge funds and large institutions have $8.73M invested in aTyr Pharma in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 7 closing their positions.
14% more capital invested
Capital invested by funds: $7.68M → $8.73M (+$1.05M)
0.48% more ownership
Funds ownership: 2.87% → 3.35% (+0.48%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
11% less funds holding
Funds holding: 27 → 24 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.59M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.24M |
| 3 |
Renaissance Technologies
New York
|
+$148K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$20K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$823K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$67K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$58K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$52K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$45K |
ATYR Hedge Fund Activity: Q2 2019 in Review
24 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2019, worth a combined $8.73M — up 14% from $7.68M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATYR and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Federated Hermes, opening a new position worth an estimated $3.59M. The largest seller was Polaris Venture Management Co V, cutting an estimated $823K.
- 24 institutional investors held aTyr Pharma (ATYR) as of Q2 2019, down from 27 in Q1 2019.
- Funds reported $8.73M of aTyr Pharma stock for Q2 2019, up 14% quarter-over-quarter.
- 4 funds opened new aTyr Pharma positions in Q2 2019 and 7 closed out, a net change of -3 holders.
- The largest aTyr Pharma buyer in Q2 2019 was Federated Hermes, an estimated $3.59M added.
- The largest aTyr Pharma seller in Q2 2019 was Polaris Venture Management Co V, an estimated $823K sold.
Based on aggregated 13F filings for Q2 2019.